Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy

GIMS Greater Noida expands paediatric orthopaedic care under Healthium's CSR initiative

Supported by Plan International, the partnership will help treat over 1,000 children annually

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD

This is an exciting and meaningful milestone for GRIN Therapeutics

World Asthma Day: Apollo Spectra Hospital urges early diagnosis and treatment adherence

Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows

Karunanithi Ponnusamy elevated to President – Animal Health Business at Alembic Pharma

With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives

Sankara Eye Hospital hosts ‘CSSD 360’ workshop on sterilisation and patient safety

Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance

FDA advisory panel narrowly withholds support for AstraZeneca’s combo in breast cancer

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor